COMPARATIVE EVALUATION OF MENTHOL AND EUGENOL AS SKIN PENETRATION ENHANCERS IN DICLOFENAC SODIUM TRANSDERMAL PATCHES
Article Sidebar
Main Article Content
Abstract
Innovations in the area of drug delivery are taking place at a much faster pace as compared with the last two decades.
Improved patient compliance and effectiveness are inextricable aspects of new drug delivery systems. Transdermal drug
delivery system (TDDS) is one of the systems lying under the category of controlled drug delivery, in which deliver the
drug through the skin in a predetermined and controlled rate. TDDS are adhesive drug-containing devices of defined
surface area that delivers a predetermined amount of drug to the surface of intact skin at a pre-programmed rate to reach
the systemic circulation. Transdermal delivery provides a leading edge over injectable and oral routes by increasing
patient compliance and avoiding first-pass metabolism, respectively. In the present investigation formulation F1 to F4
were prepared by using EC, PEG, PVA Acetone, Eugenol and Menthol with solvent evaporation technique. The prepared
patches F1 to F4 were evaluated for few physicochemical studies and all are within the limits. The in-vitro drug diffusion
studies were done by using modified dissolution apparatuses Franz diffusion cell. Among all the formulations F4 was
shown optimum drug release 99% for a period of 12h. This may be due to the presence of natural penetration enhancer
Eugenol which promotes the penetration of drug. Hence it is concluded that the Eugenol is Good Penetration enhancer
for the prepared transdermal patches which when compared to menthol.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
How to Cite
References
Tiwary AK, Sapra B, Jain S. Innovation in transdermal drug delivery: Formulation and techniques. Recent Pat Drug Deliv Formul 2007; 1:23-36.
Chong S, Fung HL, In: Hadgraft J, Guy RH, editors.Transdermal drug delivery development issues and research initiatives. New York: Marcel Dekker; 1989. p. 135-54.
Ansel HC, Allen LV and Popovich NG. Pharmaceutical dosage forms and drug delivery system. 7th ed. New York: Lipponcott Williams and Wilkins; 2002.
Patel RP, Baria AH. Formulation and evaluation consideration of transdermal drug delivery system. Int J Pharm Res 2011; 3:1-9.
Kumar JA, Pullakandam N, Prabu SL, Gopal V. Transdermal drug delivery system: An overview. Int J Pharm Sci Rev Res 2010; 3:49-54.
Williams A. London: Pharmaceutical Press; 2003.Transdermal and Topical Drug Delivery.
Prausnitz MR, Mitragotri S, Langer R. Current status and future potential of transdermal drug delivery.Nat Rev Drug Discov. 2004; 3:115–124. [PubMed]
Tanwar H, Sachdeva R. TRANSDERMAL DRUG DELIVERY SYSTEM: A REVIEW. Int J Pharm Sci Res.2016; 7(6): 2274-2290
Prodduturi S, Westenberger BJ, Buhse L. Reservoir Based Fentanyl Transdermal Drug Delivery Systems: Effect of Patch Age on Drug Release and Skin Permeation. Pharm Res. 2009; 26(6): 1344–1352.
Rani S, Saroha K, Transdermal patches a successful tool in Transdermal Drug Delivery System: An overview. Der Pharmacia Sinica. 2011; 2(5): 17-29.
Prabhakar D, Sreekanth. Transdermal Drug Delivery Patches: A Review. J drug delivther. 2013; 3(4): 231 221.
Rastogi V, Yadav P. Transdermal drug delivery system: An overview. Asian J Pharm. 2012; 6(3): 161.